Citations

Clear

1792 citation(s) found for "Stephanie".

Abstract PD3-4: A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
Goetz, MP, Suman, VA, Reid, J, Northfelt, DW, Mahr, MA, Dockter, Travis , Haluska, P., Kuffel, Mary J., Burhow, Sarah A., McGovern, Renee M., Collins, Justin, Streicher, Howard , Hawse, JR, Erlichman, Charles , Ingle, JN, Ames, M, Suman, VJ, Safgren, Stephanie L.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 24_Supplement | Pages: PD3-4-PD3-4

10.1158/0008-5472.sabcs13-pd3-4 Get It

Abstract Background: In AI refractory MBC, TAM anti-tumor activity is limited (median PFS 4.5 months). In patients (pts) receiving TAM in the adjuvant and metastatic setting, breast cancer recurrence has been shown to differ based upon CYP2D6 genotype and Endx exposure. In collaboration with NCI, Z-Endx (NSC #750393) was synthesized and preclinical pharmacology studies demonstrated that oral Z- Endx resulted in > 20 fold Endx exposure compared to an equivalent dose of TAM and significantly greater anti-tumor activity than TAM in AI sensitive and resistant MCF7 xenografts. We conducted a phase I study of Z-Endx in women with ER+, AI refractory MBC to identify dose-limiting toxicities (DLT), a maximum tolerated dose (MTD) and a dose associated with steady state concentrations (Css) of ≥ 2 uM, based on the IC50 of recently identified Endx substrates: PKC and PI3K. Methods: Pts were enrolled to an accelerated titration schedule (2 pts/dose level) until moderate toxicity or DLT, and then to a 3+3 design. Z-Endx was administered orally once daily (28 day cycle). Eye exams were performed at baseline, end of cycle 2, and after 6 cycles. PK was performed on days 1-2, 3, 7, 14, and 28, and prior to subsequent cycles. Results: 23 women with AI refractory MBC (median 56 yrs, range 41-83) received Z-Endx once daily encompassing 7 dose levels (Table 1). The median number of prior chemotherapies and hormonal therapies in the metastatic setting were 2 and 2, respectively. Dose escalation continues at 160 mg/day and the MTD has yet to be determined. Cmax and AUC increased in a dose-dependent manner. A 20 and 100 mg/day dose yields Css of 0.39 and 2.48 uM, respectively. Significant anti-tumor activity was observed including 1 pt (100 mg/day) with a PR lasting 225 days; 1 pt (80 mg/day) with a 30% reduction in tumor size (PFS 169 days) and 2 pts (60 and 80 mg/day) with stable disease for >270 days. No eye toxicity was observed. Conclusions: In women with AI refractory MBC, the MTD of Z-Endx HCl has not been determined but Endx Css concentrations of > 2 uM and substantial anti-tumor activity has been observed. Following completion of the 160 mg/day dose, expansion at 20 and 100 mg/day will commence to perform translational studies and further characterize Endx pk. A randomized phase II examining two different doses of Z-Endx is planned in AI refractory MBC. Supported in part by CA 133049, CA69912, CA15083, CA116201, and CA15083. Table 1Dose Level (mg/day)Number of Treatment CyclesModerate or Severe Toxicities ReportedTumor ResponseProgression-free Survival (days)28 day Z-Endx Css (uM) 20 (n = 2)2; 3Gr 2 hot flashes (1 pt)----60; 850.39 40 (n = 2)2; 6noneStable (1 pt)61; 1670.66 60 (n = 6)1; 2; 2; 5; 8; 14Gr 4 Triglycerides (1 pt);Gr 3 thromboembolic event (1 pt); Gr 2 hot flashes, anemia, and hypoalbuminemia (1 pt)Stable (3 pts)125+; 56; 57; 132; 232; 4331.01 80 (n = 3)4; 6; 10Gr 2 hot flashesStable (3 pts)113; 169; 2961.61 100 (n = 3)1; 2; 8Gr 2 nausea (1 pt); Gr 2 irritability (1 pt)PR (1 pt)30; 56; 2252.48 120 (n = 3)1; 2; 4Gr 2 hypersomnia, paresthesia, and peripheral sensory neuropathy (1 pt)—39; 54; 1082.18 * Bold face toxicities occurred during cycle 1 Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD3-4.
Detection and Recognition of Stop Consonants by Normal.Hearing and Hearing Impaired Listeners
Turner, Christopher W. , Fabry, David A., Barrett, Stephanie, Horwitz, Amy R.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | July 29, 2014 | Volume: 35 | Issue: 4 | Pages: 942-949

10.1044/jshr.3504.942 | PMID 1405550 Get It

This study examined the possibility that hearing-impaired listeners, in addition to displaying poorer-than-normal recognition of speech presented in background noise, require a larger signal-to-noise ratio for the detection of the speech sounds. Psychometric functions for the detection and recognition of stop consonants were obtained from both normal-hearing and hearing-impaired listeners. Expressing the speech levels in terms of their short-term spectra, the detection of consonants for both subject groups occurred at the same signal-to-noise ratio. In contrast, the hearing-impaired listeners displayed poorer recognition performance than the normal-hearing listeners. These results imply that the higher signal-to-noise ratios required for a given level of recognition by some subjects with hearing loss are not due in part to a deficit in detection of the signals in the masking noise, but rather are due exclusively to a deficit in recognition.
What Is the Gold Standard for Comprehensive Interinstitutional Communication of Perioperative Information for Thyroid Cancer Patients? A Comparison of Existing Electronic Health Records with the Current American Thyroid Association Recommendations
Reis, Laura L. Dos, Tuttle, R. Michael , Alon, Eran E. , Bergman, Donald A., Bernet, Victor , Brett, Elise M., Cobin, Rhoda H., Doherty, Gerard M. , Harris, Jeffrey , Klopper, Joshua , Lupo, Mark A. , Milas, Mira , Macháč, Josef, Orloff, Lisa A. , Randolph, Gregory W. , Ross, Douglas S. , Smallridge, Robert C., Terris, David J. , Mehra, Saral , Scherl, Sophie, Clain, Jason B. , Urken, Mark L. , Lee, Stephanie L. , Mechanick, Jeffrey I. , Randolph, Gregory William , Tufano, Ralph Patrick

Mayo Clinic

Thyroid® | July 18, 2014 | Volume: 24 | Issue: 10 | Pages: 1466-1472

10.1089/thy.2014.0209 | PMID 25036190 Get It

Background: Appropriate management of well-differentiated thyroid cancer requires treating clinicians to have access to critical elements of the patient's presentation, surgical management, postoperative course, and pathologic assessment. Electronic health records (EHRs) provide an effective method for the storage and transmission of patient information, although most commercially available EHRs are not intended to be disease-specific. In addition, there are significant challenges for the sharing of relevant clinical information when providers involved in the care of a patient with thyroid cancer are not connected by a common EHR. In 2012, the American Thyroid Association (ATA) defined the critical elements for optimal interclinician communication in a position paper entitled, “The Essential Elements of Interdisciplinary Communication of Perioperative Information for Patients Undergoing Thyroid Cancer Surgery.” Summary: We present a field-by-field comparison of the ATA's essential elements as applied to three contemporary electronic reporting systems: the Thyroid Surgery e-Form from Memorial Sloan-Kettering Cancer Center (MSKCC), the Alberta WebSMR from the University of Calgary, and the Thyroid Cancer Care Collaborative (TCCC). The MSKCC e-form fulfills 21 of 32 intraoperative fields and includes an additional 14 fields not specifically mentioned in the ATA's report. The Alberta WebSMR fulfills 45 of 82 preoperative and intraoperative fields outlined by the ATA and includes 13 additional fields. The TCCC fulfills 117 of 120 fields outlined by the ATA and includes 23 additional fields. Conclusions: Effective management of thyroid cancer is a highly collaborative, multidisciplinary effort. The patient information that factors into clinical decisions about thyroid cancer is complex. For these reasons, EHRs are particularly favorable for the management of patients with thyroid cancer. The MSKCC Thyroid Surgery e-Form, the Alberta WebSMR, and the TCCC each meet all of the general recommendations for effective reporting of the specific domains that they cover in the management of thyroid cancer, as recommended by the ATA. However, the TCCC format is the most comprehensive. The TCCC is a new Web-based disease-specific database to enhance communication of patient information between clinicians in a Health Insurance Portability and Accountability Act (HIPAA)-compliant manner. We believe the easy-to-use TCCC format will enhance clinician communication while providing portability of thyroid cancer information for patients.
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Dimopoulos, Meletios Α. , Kastritis, Efstathios , Owen, Roger G., Kyle, Robert A. , Morra, Enrica, Leleu, Xavier , García‐Sánz, Ramón , Munshi, Nikhil C. , Terpos, Evangelos , Ghobrial, Irene M. , Morel, Pierre , Maloney, David G. , Rummel, Mathias , Leblond, Véronique , Advani, Ranjana H. , Kyriakou, Charalampia , Barlogie, Bart , Gregory, Stephanie A., Kimby, Eva , Merlini, Giampaolo , Landgren, Ola , Anderson, Kenneth C. , Gertz, Morie A. , Thomas, Sheeba K. , Treon, Steven P. , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Advani, Ranjana H , Kastritis, Efstathios , Garcia-Sanz, Ramon , Ghobrial, Irene M

Mayo Clinic

Blood | July 16, 2014 | Volume: 124 | Issue: 9 | Pages: 1404-1411

10.1182/blood-2014-03-565135 | PMID 25027391 Get It

Abstract Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
An investigation into false‐negative transthoracic fine needle aspiration and core biopsy specimens
Minot, Douglas M., Gilman, Elizabeth A. , Aubry, Marie‐Christine, Voss, Jesse S. , Epps, Sarah G. Van, Tuve, Delores J, Sciallis, Andrew P. , Henry, Michael , Salomão, Diva R. , Carlson, Stephanie K., Clayton, Amy C., Aubry, Marie-Christine, Lee, Peter

Mayo Clinic

Diagnostic Cytopathology | May 28, 2014 | Volume: 42 | Issue: 12 | Pages: 1063-1068

10.1002/dc.23169 | PMID 24866385 Get It

Transthoracic fine needle aspiration (TFNA)/core needle biopsy (CNB) under computed tomography (CT) guidance has proved useful in the assessment of pulmonary nodules. We sought to determine the TFNA false‐negative (FN) rate at our institution and identify potential causes of FN diagnoses. Medical records were reviewed from 1,043 consecutive patients who underwent CT‐guided TFNA with or without CNB of lung nodules over a 5‐year time period (2003–2007). Thirty‐seven FN cases of “negative” TFNA/CNB with malignant outcome were identified with 36 cases available for review, of which 35 had a corresponding CNB. Cases were reviewed independently (blinded to original diagnosis) by three pathologists with 15 age‐ and sex‐matched positive and negative controls. Diagnosis (i.e., nondiagnostic, negative or positive for malignancy, atypical or suspicious) and qualitative assessments were recorded. Consensus diagnosis was suspicious or positive in 10 (28%) of 36 TFNA cases and suspicious in 1 (3%) of 35 CNB cases, indicating potential interpretive errors. Of the 11 interpretive errors (including both suspicious and positive cases), 8 were adenocarcinomas, 1 squamous cell carcinoma, 1 metastatic renal cell carcinoma, and 1 lymphoma. The remaining 25 FN cases (69.4%) were considered sampling errors and consisted of 7 adenocarcinomas, 3 nonsmall cell carcinomas, 3 lymphomas, 2 squamous cell carcinomas, and 2 renal cell carcinomas. Interpretive and sampling error cases were more likely to abut the pleura, while histopathologically, they tended to be necrotic and air‐dried. The overall FN rate in this patient cohort is 3.5% (1.1% interpretive and 2.4% sampling errors). Diagn. Cytopathol. 2014;42:1063–1068;. © 2014 Wiley Periodicals, Inc.
Youth Ice Hockey Injuries Over 16 Years at a Pediatric Trauma Center
Polites, Stephanie F. , Sebastian, Arjun S. , Habermann, Elizabeth B. , Iqbal, Corey W., Ishitani, Michael B., Stuart, Michael J. , Habermann, Elizabeth

Mayo Clinic

Pediatrics | May 27, 2014 | Volume: 133 | Issue: 6 | Pages: e1601-e1607

10.1542/peds.2013-3628 | PMID 24864187 Get It

BACKGROUND:Youth ice hockey is an exciting sport with growing participation in the United States. Updated assessment of injury patterns is needed to determine risk factors for severe injury and develop preventive efforts. The purpose of this study was to evaluate our experience as a level 1 pediatric trauma center in Minnesota treating injured youth ice hockey players.METHODS:Children ≤18 years old who presented to our institution from July 1997 to July 2013 with an injury sustained while participating in ice hockey were identified. Patient demographic information, injury characteristics, and outcomes including use of computed tomography, hospital admission, and procedures were obtained. Age- and gender-specific patterns were determined for injuries and outcomes.RESULTS:Over 16 years, 168 injuries in 155 children occurred, including 26 (15.5%) injuries in girls. Extremity injuries were most common, followed by traumatic brain injury. Injuries to the spine, face, and trunk were less common. Traumatic brain injury and injuries to the spine were most common in younger children (≤14 years old) and girls, whereas injuries to the face were most common in older players (≥15 years old). Most injuries resulted from intentional contact. Admission to the hospital was needed in 65 patients, including 14 (8.3%) who needed intensive care. A major procedure was needed by 23.2% of patients because of their injuries.CONCLUSIONS:Youth ice hockey trauma can be severe, necessitating a thorough evaluation of injured children. Injury patterns are influenced by age and gender, providing an opportunity for targeted preventive efforts.
Pooling Prospective Studies to Investigate the Etiology of Second Cancers
Black, Amanda , Gibson, Todd M. , Park, Yikyung , Weinstein, Stephanie J. , Andreotti, Gabriella , Purdue, Mark P. , Fraumeni, Joseph F., Hartge, Patricia, Tucker, Margaret A. , Hoover, Robert N. , Cerhan, James R. , Zeleniuch‐Jacquotte, Anne , Curtis, Rochelle E. , Elena, Joanne W. , González, Amy Berrington de , Morton, Lindsay M. , Shiels, Meredith S. , Robien, Kim , Albanes, Demetrius , Freeman, Laura E. Beane , Sampson, Joshua N. , Cerhan, James R , Morton, Lindsay M , Berrington de Gonzalez, Amy , Gibson, Todd , Zeleniuch-Jacquotte, Anne

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 15, 2014 | Volume: 23 | Issue: 8 | Pages: 1598-1608

10.1158/1055-9965.epi-14-0191 | PMID 24832874 Get It

Abstract Background: With over 13 million cancer survivors in the United States today, second cancers are of rapidly growing importance. However, data on nontreatment risk factors for second cancers are sparse. We explored the feasibility of pooling data from cohort studies of cancer incidence to investigate second cancer etiology. Methods: We combined data from five prospective studies including more than 800,000 individuals. We compared study designs and populations; evaluated availability of and ability to harmonize risk factor data; compared incidence and survival for common first primary malignancies and incidence of second primary malignancies; and estimated sample size requirements. Results: Overall, 96,513 incident, first primary malignancies were diagnosed during 1985 to 2009. Incidence rates and survival following the first primary varied among the cohorts, but most of the heterogeneity could be explained by characteristics of the study populations (age, sex, smoking, and screening rates). A total of 7,890 second primary cancers (excluding original primary site) were identified, yielding sufficient statistical power (≥80%) for detecting modest associations with risk of all second cancers among survivors of common first primary malignancies (e.g., colorectal cancer); however, there were insufficient events for studying survivors of rarer cancers or identifying risk factors for specific second cancers. Conclusions: Pooling data from cohort studies to investigate nontreatment risk factors for second primary cancers seems feasible but there are important methodologic issues—some of which are barriers to specific research questions—that require special attention. Impact: Increased understanding of nontreatment risk factors for second cancers will provide valuable prevention and surveillance information. Cancer Epidemiol Biomarkers Prev; 23(8); 1598–608. ©2014 AACR.
Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity Conditioning Regimens
Khera, Nandita , Emmert, Amy, Storer, Barry E. , Alyea, Edwin P. , Lee, Stephanie J. , Sandmaier, Brenda M, Sandmaier, Brenda M , Lee, Stephanie J

Mayo Clinic

The Oncologist | May 6, 2014 | Volume: 19 | Issue: 6 | Pages: 639-644

10.1634/theoncologist.2013-0406 | PMID 24797822 Get It

Abstract Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.
Contraception and Hormonal Management in the Perimenopause
Long, Margaret E. , MacLaughlin, Kathy L. , Pruthi, Sandhya , Casey, Petra M., Faubion, Stephanie S.

Mayo Clinic

Journal of Women's Health | April 28, 2014 | Volume: 24 | Issue: 1 | Pages: 3-10

10.1089/jwh.2013.4544 | PMID 24773233 Get It

Induction of CD56 and TCR-Independent Activation of T Cells with Aging
Lemster, Bonnie , Michel, Joshua J. , Montag, David T. , Paat, John J., Studenski, Stephanie A. , Vallejo, Abbe N. , Newman, Anne B.

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 180 | Issue: 3 | Pages: 1979-1990

10.4049/jimmunol.180.3.1979 | PMID 18209097 Get It

Abstract Degeneration of the thymus and severe contraction of the T cell repertoire with aging suggest that immune homeostasis in old age could be mediated by distinct effectors. Therefore, receptors expressed on T cells as they undergo senescence in vitro, as well as those displayed by circulating T cells during normal chronologic aging, were examined. Monitoring of T cells driven to senescence showed de novo induction of CD56, the prototypic receptor of NK cells. Analysis of fresh T cells in peripheral blood showed an age-dependent induction of CD56. These unusual T cells expressed high levels of Bcl2, p16, and p53, and had limited, or completely lost, ability to undergo cell division, properties consistent with senescence. CD56 cross-linking without TCR ligation on CD56+ T cells resulted in extensive protein phosphorylation, NF-κB activation, and Bax down-regulation. CD56 cross-linking was also sufficient to drive production of various humoral factors. These data suggest that the immunologic environment in old age is functionally distinct, rather than being a dysfunctional version of that seen at a young age. CD56+ T cells are unique effectors capable of mediating TCR-independent immune cascades that could be harnessed to enhance protective immunity in the elderly.